Mid-Sized Japan Makers to Take Heaviest Hit from April Price Cut, Bigger Peers See Smaller Reductions: Jiho Survey

Many mid-sized Japanese drug makers will suffer price cuts larger than the industry average of 7.48% in an upcoming drug price revision in April, while the majority of their bigger compatriots and foreign players will take smaller-than-average reductions, a Jiho...read more